Traws Pharma, Inc. Noncontrolling Interest, Increase from Subsidiary Equity Issuance
Traws Pharma, Inc. (TRAW) reported Noncontrolling Interest, Increase from Subsidiary Equity Issuance of $500.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2016-03-28.
Discontinued › Shareholders' Equity
us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance · last filed 2016-03-28
- Traws Pharma, Inc. noncontrolling interest, increase from subsidiary equity issuance for fiscal 2014 was $500.00K.
| Period end | Noncontrolling Interest, Increase from Subsidiary Equity Issuance 12 month |
|---|---|
| 2014-12-31 | $500.00K 10-K · filed 2016-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |